Intellectual Property Delenex takes great care in managing its comprehensive intellectual property rights portfolio and exclusive license agreements with Alcon, Inc. in the relevant markets. Multiple patent applications have entered the national phases in numerous countries. They do not only cover the technology but also antibody products and applications.

Thirteen patents are issued or allocated to grant covering methods to identify stable antibody frameworks, the composition of such frameworks, randomized gene sequence libraries, methods to identify target-specific antibodies as well as selected antibody sequences and variants thereof.